Solventum Corporation (SOLV) — Analysis Summary
Solventum Corporation (SOLV) has a market cap of $14.52B with year-over-year revenue growth of +0.9%. Net margin stands at 18.7%. The stock trades at a P/E ratio of 10.1.
Key Takeaways
- Revenue changed +0.9% year-over-year
- Net margin of 18.7%
- P/E ratio of 10.1
Compared to other companies in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector, SOLV posted revenue growth of +0.9% and trades at a P/E of 10.1.
Solventum Corporation (SOLV)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsWatch List
Some caution signals are active and should be weighed alongside the valuation work.
The latest filing shows negative free cash flow.
In spring 2024, 3M spun out its legacy healthcare segment as a stand-alone firm, Solventum. At that time, the firm comprised four segments. The smallest one—purification and filtration—has since been sold. Now, medsurg is the largest business, contributing roughly 64% of consolidated revenue, and includes advanced wound care and wound prevention. Dental solutions (restorative composites and orthodontia) and health information systems (mainly revenue cycle management) each contribute 18% of total revenue.
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Employees
20,000
Headquarters
EAGAN, MN
Exchange
XNYS
At least 3 years of annual financial data required to assess competitive moat.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.